Private company

Provention Bio, Inc.

American pharmaceutical preparations company based in Lebanon. Summary from the record

Last updated Oct 19, 2026.

Overview

IndustryPharmaceutical Preparations²
HeadquartersLebanon, United States²
Incorporated inDE³
Business address55 Broad Street, 2Nd Floor, Red Bank, Nj 07701³
Filer categoryNon-accelerated filer, Smaller reporting company³
Legal formCorporation²
LEI5493003LM26XAVJKLD34²
StatusActive²
LEI statusLapsed (not renewed)²
Registered addressC/O Corporation Service Company, 19808 Wilmington, United States²
Registered withDivision of Corporations, Department of State, 6172593²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-993.9%Operating margin⁴

-880.7%Net margin⁴

824.4%Revenue growth, 2022⁴

-93.2%Return on equity⁴

0.19×Debt to equity⁴

-$76.2MFree cash flow⁴

Where the money goes

Where each dollar of revenue went, fiscal 2022

Research and developmentSelling, general and admin

Research and development49¢$75.8M
Selling, general and admin42¢$64.1M
Interest1¢$1.0M
Income tax9¢$13.4M

Out of $12.9M in revenue.⁴ The company lost money this year.

Financial statements

Revenue⁴$12.9M in 2022+824% since 2021

Operating income⁵⁶⁷⁴-$128.2M in 2022+1302% since 2017

Net income⁵⁶⁷⁴-$113.6M in 2022+1143% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022
Revenue					$1.4M⁴	$12.9M⁴
Research and development	$7.7M⁵	$22.6M⁶	$36.4M⁷	$66.4M⁴	$69.6M⁴	$75.8M⁴
Selling, general and admin				$33.3M⁴	$47.3M⁴	$64.1M⁴
Operating expenses					$117.0M⁴	$141.1M⁴
Operating income	-$9.1M⁵	-$26.8M⁶	-$44.4M⁷	-$99.7M⁴	-$115.6M⁴	-$128.2M⁴
Interest						$1.0M⁴
Income before tax					-$115.4M⁴	-$127.0M⁴
Income tax		-$187.0K⁶		-$523.0K⁴	-$1.0M⁴	-$13.4M⁴
Net income	-$9.1M⁵	-$26.5M⁶	-$43.3M⁷	-$98.6M⁴	-$114.4M⁴	-$113.6M⁴
Earnings per share				-$1.88⁴	-$1.81⁴	-$1.52⁴
Shares (weighted, basic)					63.1M shares⁴	74.7M shares⁴

Total assets¹¹⁵⁶⁷⁴$236.9M in 2022+956% since 2017

Total liabilities¹¹⁶⁷⁴$115.0M in 2022+4953% since 2017

Shareholders’ equity⁵⁶⁷⁴$121.8M in 2022

Cash¹¹⁵⁶⁷⁴$44.0M in 2022+102% since 2017

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash		$21.8M¹¹	$58.5M⁵	$39.2M⁶	$102.3M⁷	$78.2M⁴	$44.0M⁴
Receivables							$1.4M⁴
Inventory							$1.2M⁴
Current assets				$86.0M⁶	$126.6M⁷	$101.1M⁴	$174.6M⁴
Property, plant and equipment						$2.0M⁴	$2.2M⁴
Intangible assets							$59.6M⁴
Total assets		$22.4M¹¹	$61.5M⁵	$86.0M⁶	$128.5M⁷	$135.6M⁴	$236.9M⁴
Accounts payable						$3.5M⁴	$6.8M⁴
Current liabilities		$1.3M¹¹	$1.9M⁵	$3.8M⁶	$16.7M⁷	$22.8M⁴	$90.4M⁴
Long-term debt							$23.5M⁴
Total liabilities		$2.3M¹¹	$1.9M¹¹	$3.8M⁶	$17.4M⁷	$24.9M⁴	$115.0M⁴
Retained earnings						-$292.1M⁴	-$405.6M⁴
Shareholders’ equity	-$165.0K⁵	-$6.0M⁶	$59.7M⁷	$82.2M⁴	$111.1M⁴	$110.7M⁴	$121.8M⁴
Shares outstanding		10.0M shares¹¹	37.4M shares⁵	47.7M shares⁶	56.5M shares⁷	63.4M shares⁴	87.7M shares⁴

Cash from operations⁵⁶⁷⁴-$75.4M in 2022+1445% since 2017

Capital spending⁴$795.0K in 2022−28% since 2020

Free cash flow⁴-$76.2M in 2022−2% since 2020

Fiscal year	2017	2018	2019	2020	2021	2022
Cash from operations	-$4.9M⁵	-$22.6M⁶	-$36.1M⁷	-$76.3M⁴	-$95.4M⁴	-$75.4M⁴
Depreciation and amortization					$387.0K⁴	$601.0K⁴
Stock-based compensation					$11.8M⁴	$19.0M⁴
Capital spending				$1.1M⁴	$961.0K⁴	$795.0K⁴
Free cash flow				-$77.4M	-$96.3M	-$76.2M
Cash from investing					-$31.1M⁴	-$88.1M⁴
Cash from financing					$102.4M⁴	$129.4M⁴

Compare Provention Bio, Inc. with another company

Leadership

Who has led Provention Bio, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Ashleigh Palmer2018–2023

President

Ashleigh Palmer2018–2020

Chief financial officer

Chief operating officer

Eleanor Ramos2018–2019

20202025

Chief executive officerAshleigh Palmer Jul 3, 2018 to Apr 27, 2023¹²
PresidentAshleigh Palmer Jul 3, 2018 to Aug 18, 2020¹²
Chief financial officerThierry Chauche Dec 1, 2021 to Apr 27, 2023¹³
Chief financial officerAndrew T. Drechsler Jul 3, 2018 to May 14, 2021¹⁴
Chief operating officerEleanor Ramos Jul 3, 2018 to Dec 26, 2019¹⁵

Board members and other officers (17)

Chief Accounting OfficerJustin Vogel Jan 5, 2023 to Apr 27, 2023¹⁶
Chief People OfficerSarah O'Brien Sep 19, 2022 to Jan 11, 2023¹⁷
Chief Operations OfficerMiyoko Christina Yi Dec 20, 2021 to Apr 27, 2023¹⁸
Chief Quality OfficerBenedict Osorio Dec 23, 2021 to Apr 27, 2023¹⁹
Chief Commercial OfficerJason Hoitt Jan 8, 2020 to Apr 27, 2023²⁰
Chief Medical OfficerEleanor Ramos Jul 16, 2020 to Apr 27, 2023²¹
Board memberRita Jain Jan 5, 2023 to Apr 27, 2023²²
Board memberNancy Wysenski May 21, 2020 to Apr 27, 2023²³
Board memberJohn Kenneth Jenkins Aug 11, 2020 to Apr 27, 2023²⁴
Board memberJeffrey Bluestone Mar 28, 2019 to May 18, 2022²⁵
Board memberSean M. Doherty Sep 30, 2019 to May 18, 2022²⁶
Board memberAnthony Digiandomenico Jul 3, 2018 to Jun 17, 2020²⁷
Board memberAshleigh Palmer Jul 3, 2018 to Feb 14, 2023¹²
Board memberCameron Gray Jul 3, 2018 to Jul 26, 2018²⁸
Board memberWayne Pisano Jul 3, 2018 to Apr 27, 2023²⁹
Board memberAvery W. Catlin Sep 5, 2018 to Apr 27, 2023³⁰
General counselHeidy King-Jones Aug 3, 2020 to Apr 27, 2023³¹

Timeline

Jul 3, 2018New chief executive Ashleigh Palmer becomes CEO¹²

Filings

156 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 24 major events, 81 insider forms, 10 large holders, 35 other. The latest 20:

May 8, 202315-12G EDGAR
Apr 28, 2023EFFECT EDGAR
Apr 28, 2023EFFECT EDGAR
Apr 28, 2023EFFECT EDGAR
Apr 28, 2023SC 13G/A EDGAR
Apr 28, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR
Apr 27, 20234 EDGAR

The 156 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 3 buys and 13 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Apr 14, 2023	Sessa Capital IM GP, LLC10% owner	Sale	2,190,549	$24.32	$53.3M	Form 4
Feb 13, 2023	Leon FranciscoChief Scientific Officer	Sale	25,985	$10.04	$260.9K	Form 4
Feb 13, 2023	Palmer AshleighDirector and CEO	Sale	25,835	$10.04	$259.4K	Form 4
Feb 10, 2023	Leon FranciscoChief Scientific Officer	Sale	50,000	$10.11	$505.5K	Form 4
Feb 10, 2023	Hoitt JasonChief Commercial Officer	Sale	4,500	$10.00	$45.0K	Form 4
Feb 10, 2023	Palmer AshleighDirector and CEO	Sale	50,000	$10.11	$505.5K	Form 4
Jan 18, 2023	Palmer AshleighDirector and CEO	Sale	24,165	$10.27	$248.2K	Form 4
Jan 18, 2023	Leon FranciscoChief Scientific Officer	Sale	24,015	$10.27	$246.6K	Form 4
Jan 18, 2023	Sessa Capital (Master), L.P.10% owner	Sale	3,000,000	$9.40	$28.2M	Form 4
Dec 29, 2022	Leon FranciscoChief Scientific Officer	Sale	187,000	$10.26	$1.9M	Form 4
Dec 27, 2022	Leon FranciscoChief Scientific Officer	Sale	10,674	$10.00	$106.7K	Form 4
Dec 23, 2022	Leon FranciscoChief Scientific Officer	Sale	375	$10.00	$3.8K	Form 4
Dec 22, 2022	Leon FranciscoChief Scientific Officer	Sale	1,568	$10.00	$15.7K	Form 4
Dec 3, 2021	Ramos EleanorChief Medical Officer	Buy	5,201	$6.49	$33.8K	Form 4
Nov 30, 2021	Palmer AshleighDirector and CEO	Buy	3,750	$6.66	$25.0K	Form 4
Nov 24, 2021	Leon FranciscoChief Scientific Officer	Buy	5,550	$7.24	$40.2K	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sessa Capital (Master), L.P.SC 13G/A, 5 filings Feb 14, 2022 to Apr 28, 2023³²
ADAGE CAPITAL PARTNERS GP, L.L.C.SC 13G, 3 filings Aug 26, 2022 to Feb 21, 2023³³
Venrock Healthcare Capital Partners II, L.P.SC 13G/A, 1 filing Feb 14, 2023³⁴
PERCEPTIVE ADVISORS LLCSC 13G/A, 1 filing Feb 14, 2022³⁵

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARProvention Bio, Inc. filings on SEC EDGAR
2
GLEIFProvention Bio, Inc. LEI record (5493003LM26XAVJKLD34)
3
SEC EDGARProvention Bio, Inc. filings on SEC EDGAR
4
SEC EDGARProvention Bio, Inc. 10-K for fiscal 2022
5
SEC EDGARProvention Bio, Inc. 10-K for fiscal 2017
6
SEC EDGARProvention Bio, Inc. 10-K for fiscal 2018
7
SEC EDGARProvention Bio, Inc. 10-K for fiscal 2019
8
SEC EDGARProvention Bio, Inc. 10-Q for fiscal 2022
9
SEC EDGARProvention Bio, Inc. 10-Q for fiscal 2022
10
SEC EDGARProvention Bio, Inc. 10-Q for fiscal 2022
11
SEC EDGARProvention Bio, Inc. 10-K for fiscal 2017
12
SEC EDGARAshleigh Palmer, Chief executive officer
13
SEC EDGARThierry Chauche, Chief financial officer
14
SEC EDGARAndrew T. Drechsler, Chief financial officer
15
SEC EDGAREleanor Ramos, Chief operating officer
16
SEC EDGARJustin Vogel, Chief Accounting Officer
17
SEC EDGARSarah O'Brien, Chief People Officer
18
SEC EDGARMiyoko Christina Yi, Chief Operations Officer
19
SEC EDGARBenedict Osorio, Chief Quality Officer
20
SEC EDGARJason Hoitt, Chief Commercial Officer
21
SEC EDGAREleanor Ramos, Chief Medical Officer
22
SEC EDGARRita Jain, Board member
23
SEC EDGARNancy Wysenski, Board member
24
SEC EDGARJohn Kenneth Jenkins, Board member
25
SEC EDGARJeffrey Bluestone, Board member
26
SEC EDGARSean M. Doherty, Board member
27
SEC EDGARAnthony Digiandomenico, Board member
28
SEC EDGARCameron Gray, Board member
29
SEC EDGARWayne Pisano, Board member
30
SEC EDGARAvery W. Catlin, Board member
31
SEC EDGARHeidy King-Jones, General counsel
32
SEC EDGARSessa Capital (Master), L.P. SC 13G/A on Provention Bio, Inc.
33
SEC EDGARADAGE CAPITAL PARTNERS GP, L.L.C. SC 13G on Provention Bio, Inc.
34
SEC EDGARVenrock Healthcare Capital Partners II, L.P. SC 13G/A on Provention Bio, Inc.
35
SEC EDGARPERCEPTIVE ADVISORS LLC SC 13G/A on Provention Bio, Inc.